Traditional clinical lab testing, with its need for complex machinery, specialized operation, and dedicated laboratory environments, presents clear challenges: it’s inconvenient, time-consuming, and costly. This complexity is traditionally justified by the need for precision to ensure test accuracy, a concept known as the “precision paradigm.”

At Imost Arabia, we have shifted away from this conventional approach by adopting and developing what we call the “intelligent fault-tolerant paradigm.” This new framework, along with other groundbreaking innovations, allows for clinical lab-quality results using simpler devices that remain reliable even under less-than-perfect conditions involving samples, devices, processes, and operations.

One major hurdle in traditional point-of-care (POC) testing is the requirement for multiple instruments and various sample holders for different tests. Our iMOST technology overcomes this by utilizing a single, versatile platform. This unique sample holder and instrument can handle various sample types—including blood, saliva, urine, swab, sputum, breath, mucus, and tissue—and perform a wide range of assays, such as immunoassays, colorimetric tests, cytology, pathology, and nucleic acid tests, across diverse biomarkers like cells, proteins, nucleic acids, and small molecules.

iMOST features several additional innovations designed to enhance user experience: the device requires only tiny sample volumes (5-10 µL), operates quickly (delivering results within minutes), and integrates seamlessly with mobile devices for real-time monitoring and calibration. It’s easy to use, reliable, requires low maintenance, and is cost-effective to operate. Furthermore, the intelligent fault-tolerant design enables the iMOST readers to be compact and easily manufactured on a large scale at low cost.

The iMOST (Instant Mobile Self-Test), a first-of-its-kind technology, embodies a completely new approach by integrating advanced nanotechnology, imaging, Nano-Enabled Artificial Intelligence/Machine Learning (NEAM), and innovative bio/chemical processes into diagnostic testing.